Therapeutic effects of calcium & vitamin D supplementation in women with PCOS

Complementary Therapies in Clinical Practice

Volumn 18, Issue 2, 2012, Pages 85-88

  Firouzabadi, Raziah dehghani ^a   Aflatoonian, Abbas ^a   Modarresi, Seyedehzalfa ^b   Sekhavat, Leila ^c   MohammadTaheri, Somayeh ^d  

^a Shahid Sedughi University of Medical Sciences and Health Services   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Calcium; Metformin; Polycystic ovary syndrome; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; ANTIDIABETIC AGENT; CALCIUM; DRUG DERIVATIVE; METFORMIN; VITAMIN D;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERANDROGENISM; MENSTRUAL CYCLE; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; WEIGHT REDUCTION;

ADULT; CALCIUM; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; MENSTRUAL CYCLE; METFORMIN; OVARIAN FOLLICLE; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY; WEIGHT LOSS; YOUNG ADULT;

EID: 84859720015     PISSN: 17443881     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctcp.2012.01.005     Document Type: Article

References (29)

1. Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS society. Fertil Steril 2009, 91:456-488.
2. Escobar-Morreale H.F. Polycystic ovary syndrome: treatment strategies and management. Expert Opin Pharmacother 2008, 9(17):2995-3008.
3. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 2005, 352:1223-1236.
4. Cussons A.J., Stuckey B.G., Watts G.F. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006, 185:227-239.
5. Hahn S., Haselhorst U., Tan S., Quadbeck B., Schmidt M., Roesler S., et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006, 114:577-583.
6. Goodarzi M.O., Korenman S.G. The importance of insulin resistance in polycystic ovary syndrome. FertilSteril 2003, 80:255-258.
7. Farshchi H., Ranel A., Lovel A., Kennedy R.L. Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management. J Obstetrics Gynaecol 2007, 27(8):762-773.
8. Alvarez J.A., Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010, 2010:351-385.
9. Ciotta L., Stracquadanio M., Pagano I., Carbonaro A., Palumbo M., Gulino F. Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci 2011 May, 15(5):509-514.
10. Cussons A.J., Watts G.F., Mori T.A., Stuckey B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009, 94(10):3842-3848.
11. Muscogiuri G., Sorice G.P., Prioletta A., Policola C., Della Casa S., Pontecorvi A., et al. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity 2010, 18:1906-1910.
12. Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007, 92(6):2017-2029.
13. Zemel M.B. Role of calcium and dairy products in energy partitioning and weight management. Am J Clin Nutr 2004, 79:907-912.
14. Young K.A., Engelman C.D., Langefeld C.D., Hairston K.G., Haffner S.M., Bryer-Ash M., et al. Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. J Clin Endocrinol Metab 2009, 94(9):3306-3313.
15. Panidis D., Balaris C., Farmakiotis D., Rousso D., Kourtis A., Balaris V., et al. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem 2005, 51:1691-1697.
16. ESHRE/ASRM Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
17. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96(1):53.
18. Ullah G., Jung P., Machaca K. Modeling Ca2+ signaling differentiation during oocyte maturation. Cell Calcium 2007, 42:556-564.
19. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004, 27:2813-2818.
20. Rashidi B., Haghollahi F., Shariat M., Zayerii F. The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. Taiwan J Obstet Gynecol 2009, 48(2):142-147.
21. Thys-Jacobs S., Donovan D., Papadopoulos A., Sarrel P., Bilezikian J.P. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids 1999, 64(6):430-435.
22. Mahmoudi T., Gourabi H., Ashrafi M., Yazdi R.S., Ezabadi Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril 2010, 93(4):1208-1214.
23. Yildizhan R., Kurdoglu M., Adali E., Kolusari A., Yildizhan B., Sahin H.G., et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet 2009, 280:559-563.
24. Shakiba M., Nafei Z., Lotfi M.H., Shajari A. Prevalence of vitamin D deficiency among female students in Secondary Guidance School in Yazd city. Acta Med Iranica 2009, 47(3):209-214.
25. Rahimi A., Zarghami N., Sadigh A. Relation between vitamin D and nutritional status in healthy reproductive age women. Int J Endocrinal Metab 2006, 4:1-7.
26. Selimoglu H., Duran C., Kiyici S., Ersoy C., Guclu M., Ozkaya G., et al. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest 2010, 33(4):234-238.
27. Wehr E., Pilz S., Schweighofer N., Giuliani A., Kopera D., Pieber T.R., et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009, 161(4):575-582.
28. Mirsaeid Ghazi A.A., RaisZadeh F., Pezeshk P., Azizi F. Seasonal variation of serum 25 hydroxy D3 in residents of Tehran. J Endocrinol Invest 2004, 27(7):676-679.
29. Hashemipour S., Larijani B., Adibi H., Javadi E., Sedaghat M., Pajouhi M., et al. Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 2004, 4:38.